Haw Par Corporation Limited (HAWPY)

USD 35.95

(7.63%)

Gross Profit Summary of Haw Par Corporation Limited

  • Haw Par Corporation Limited's latest annual gross profit in 2023 was 134.88 Million SGD , up 36.85% from previous year.
  • Haw Par Corporation Limited's latest quarterly gross profit in 2024 Q2 was 32.23 Million SGD , down 0.0% from previous quarter.
  • Haw Par Corporation Limited reported a annual gross profit of 98.56 Million SGD in annual gross profit 2022, up 33.84% from previous year.
  • Haw Par Corporation Limited reported a annual gross profit of 73.64 Million SGD in annual gross profit 2021, up 50.82% from previous year.
  • Haw Par Corporation Limited reported a quarterly gross profit of 32.23 Million SGD for 2024 Q2, down 0.0% from previous quarter.
  • Haw Par Corporation Limited reported a quarterly gross profit of 31.47 Million SGD for 2023 Q1, up 34.94% from previous quarter.

Annual Gross Profit Chart of Haw Par Corporation Limited (2023 - 2001)

Historical Annual Gross Profit of Haw Par Corporation Limited (2023 - 2001)

Year Gross Profit Gross Profit Growth
2023 134.88 Million SGD 36.85%
2022 98.56 Million SGD 33.84%
2021 73.64 Million SGD 50.82%
2020 48.82 Million SGD -64.99%
2019 139.45 Million SGD -4.31%
2018 145.73 Million SGD 2.52%
2017 142.14 Million SGD 13.27%
2016 125.49 Million SGD 18.11%
2015 106.24 Million SGD 17.74%
2014 90.23 Million SGD 12.85%
2013 79.96 Million SGD 1.94%
2012 78.43 Million SGD 8.69%
2011 72.16 Million SGD -0.97%
2010 72.87 Million SGD 0.91%
2009 72.22 Million SGD 0.64%
2008 71.75 Million SGD 1.36%
2007 70.79 Million SGD -1.32%
2006 71.74 Million SGD 1.12%
2005 70.94 Million SGD 2.64%
2004 69.12 Million SGD -4.9%
2003 72.67 Million SGD -1.11%
2002 73.49 Million SGD -3.5%
2001 76.16 Million SGD 0.0%

Peer Gross Profit Comparison of Haw Par Corporation Limited

Name Gross Profit Gross Profit Difference
AstraZeneca PLC 34.69 Billion USD 99.611%
Bristol-Myers Squibb Company PFD CONV 2 34.31 Billion USD 99.607%
CSPC Pharmaceutical Group Limited 30.13 Billion USD 99.552%
Clarus Therapeutics Holdings, Inc. 11.23 Million USD -1100.392%
Novartis AG 34.18 Billion USD 99.605%
PT Kalbe Farma Tbk. 743.47 Million USD 81.857%